CD4 and cytomegalovirus retinitis: Previous studies have observed improved prognosis in CMV retinitis patients receiving HAART, specifically in terms of reduced progression, detachment, and visual loss.11,13–15 In the LSOCA report by Sugar et al,7 the investigators comment that 26 of the 29 patients with CMV retinitis and a CD4 count lower than 50/cells/mm3 had been noted to have been receiving HAART at the clinic review immediately before the ophthalmic assessment, suggesting there was either treatment failure or lack of adherence.6